Mucolin (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Mucolin, is a mucolytic agent presented as an oral formulation for oral use. It helps to reduce the viscosity of respiratory secretions and facilitates clearance of mucus in conditions such as bronchitis, COPD and sinusitis.\n\nGNH India supplies Mucolin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ambroxol Hydrochloride acts on the respiratory tract to thin and clear mucus, supporting treatment of several airway disorders.\n\nCough with thick mucus: improves sputum clearance and eases expectoration.\nAcute bronchitis: reduces mucus viscosity, aiding symptom relief.\nChronic bronchitis: supports long‑term mucus management.\nChronic obstructive pulmonary disease (COPD): assists in clearing airway secretions.\nSinusitis: helps drain sinus mucus and relieve congestion.

Ambroxol Hydrochloride is generally well tolerated, but some patients may experience adverse reactions.\n\nCommon Side Effects:\n- Nausea or upset stomach\n- Bitter or altered taste sensation\n- Diarrhoea or loose stools\n- Abdominal discomfort\n- Skin rash or mild itching\n\nSerious or Rare Side Effects:\n- Severe allergic reactions (anaphylaxis, angioedema)\n- Stevens‑Johnson syndrome or toxic epidermal necrolysis\n- Hepatic dysfunction (elevated liver enzymes)\n- Eosinophilia or blood dyscrasias\n- Persistent bronchospasm

When prescribing Ambroxol Hydrochloride, consider patient‑specific factors and monitor for potential risks.\n\nAssess renal function: adjust use in severe impairment.\nMonitor for hypersensitivity: discontinue if allergic signs appear.\nUse with caution in asthma: may provoke bronchospasm.\nAvoid in known hypersensitivity to ambroxol or related compounds.\nPregnancy and lactation: consult a physician before use.\nStore at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Ambroxol Hydrochloride may interact with other medications, requiring attention to avoid reduced efficacy or increased toxicity.\n\nMajor Interactions (Avoid):\n- Concurrent use with other mucolytics: risk of excessive thinning of mucus.\n- Combination with antitussives containing codeine: may diminish cough‑suppressant effect.\n\nModerate Interactions (Monitor Closely):\n- Bronchodilators (e.g., beta‑agonists): monitor respiratory response.\n- Certain antibiotics (e.g., macrolides): may increase gastrointestinal upset.\n- Antihistamines: possible increase in sedation or dry mouth.